Chordiant Software (CHRD) ranked among the winners in a generally upward-trending after-hours session Thursday.

Chordiant shares leapt nearly 16% after the software developer inked a contract worth some $26.5 million (a "record" 18.1 million euros), based on recent conversion rates, to "provide perpetual enterprise licenses and support" to an unnamed "leading telecommunications company." The agreement, which covers up to eighteen of the telecom firm's group companies or subsidiaries across four continents, will likely generate future orders or minimum payments for Chordiant through April 2009.

The Cupertino, Calif., company also projected below-par current-quarter results while reaffirming its fiscal 2008 guidance ranges, which cover the average analyst estimates on both top and bottom lines, per Thomson Financial. Chordiant shares were rising $1.28 to $9.40.

Elsewhere, Alexza Pharmaceuticals ( ALXA) announced that Endo Pharmaceuticals ( ENDP) will pay it $10 million up front under a license-and-development partnership covering AZ-003, a pain-treatment device that's currently in early-phase development.

The device, which uses Alexza's Staccato system inhalation technology to deliver fentanyl, treats cancer and non-cancer patients for breakthrough pain (that which "breaks through" the normal course of medication). On top of the upfront fee, Alexza may get up to another $40 million in milestone payments. Shares of Palo Alto, Calif.-based Alexza were recently up 8.1% to $8.78 in light extended trading. Endo was flat at $6.90.

Also among the late winners was student lender Sallie Mae ( SLM), lately up 2.3% to recover from its heavy stock-offering-spurred losses in the regular session. Biotech companies Genitope ( GTOP) and Dendreon ( DNDN) were recently climbing 5.1% and 6.3%, respectively.

Christopher & Banks ( CBK) was losing ground, however, after the Minnesota-based women's-apparel retailer slashed its fiscal 2008 profit estimate to between 2 cents and 5 cents a share -- at least 2 cents under Wall Street expectations. The company now expects same-store sales to be flat or down vs. last year, which compares with the prior prediction for a low- to mid-single-digit increase. In September, the income range was pegged at 6 cents to 8 cents a share.

Third-quarter earnings came in a penny per share above estimates. Still, Christopher & Banks stock was down 5.5% to $12.21 in thin trading.

Also declining after the closing bell, with recent losses of 1.1% or more, were glass-bottles maker Owens-Illinois ( OI); metals miner Coeur d'Alene Mines ( CDE); and rechargeable-batteries maker China BAK Battery ( CBAK).

More from Investing

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Adobe Isn't Just Going After Shopify With Its Latest Acquisition

Adobe Isn't Just Going After Shopify With Its Latest Acquisition

Experts Break Down GDPR Risks for Investors

Experts Break Down GDPR Risks for Investors